Combination therapy method for treating cancer using edatrexate and a taxane derivative, e.g. paclitaxel
CA 2246419 A1 · Owner: Sirotnak, Francis M. · Inventors: Fennelly, David W.; Sirotnak, Francis M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention provides combination therapy methods pharmaceutical , combinations and compositions for inducing tumor cell regression in cancer patients, particularly metastatic breast cancer patients. The combination methods, combinations and compositions employ both edatrexate and a taxane (e.g. Paclitaxel) which are administered simultaneously or sequentially. The combination therapy described here permits the administration of unusually high doses of edatrexate.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 29, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 29, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 29, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.